DE60214127D1 - Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper - Google Patents
Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörperInfo
- Publication number
- DE60214127D1 DE60214127D1 DE60214127T DE60214127T DE60214127D1 DE 60214127 D1 DE60214127 D1 DE 60214127D1 DE 60214127 T DE60214127 T DE 60214127T DE 60214127 T DE60214127 T DE 60214127T DE 60214127 D1 DE60214127 D1 DE 60214127D1
- Authority
- DE
- Germany
- Prior art keywords
- hybridomy
- production
- cell line
- monoclonal antibodies
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26685301P | 2001-02-07 | 2001-02-07 | |
| US266853P | 2001-02-07 | ||
| US32700801P | 2001-10-05 | 2001-10-05 | |
| US327008P | 2001-10-05 | ||
| PCT/EP2002/001282 WO2002062972A2 (en) | 2001-02-07 | 2002-02-07 | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60214127D1 true DE60214127D1 (de) | 2006-10-05 |
| DE60214127T2 DE60214127T2 (de) | 2007-01-11 |
Family
ID=26952068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60214127T Expired - Lifetime DE60214127T2 (de) | 2001-02-07 | 2002-02-07 | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040219633A1 (de) |
| EP (2) | EP1358318B8 (de) |
| JP (1) | JP4263485B2 (de) |
| AT (1) | ATE337395T1 (de) |
| AU (2) | AU2002252999A1 (de) |
| CA (1) | CA2435683C (de) |
| DE (1) | DE60214127T2 (de) |
| DK (2) | DK1358318T3 (de) |
| ES (2) | ES2531909T3 (de) |
| HK (1) | HK1094876A1 (de) |
| MX (1) | MXPA03006992A (de) |
| PT (2) | PT1358318E (de) |
| WO (2) | WO2002062972A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| ES2377396T3 (es) | 2002-07-01 | 2012-03-27 | Wilex Ag | Coadministración de CG250 e IL-2 o IFN-alfa para tratar cáncer tal como carcinomas de células renales |
| MXPA06013240A (es) | 2004-07-02 | 2007-02-28 | Wilex Ag | Terapia adyuvante mejorada de tumores que expresan g250. |
| WO2007065027A2 (en) * | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| WO2008091798A2 (en) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
| GB0911569D0 (en) | 2009-07-03 | 2009-08-12 | Ulive Entpr Ltd | Method for the detection of organ or tissue injury |
| US20120207672A1 (en) * | 2009-09-15 | 2012-08-16 | Wilex Ag | Selective detection of bone metastases in renal clear cell carcinoma |
| CN110208535A (zh) | 2013-02-22 | 2019-09-06 | 威丽克斯股份公司 | 基于caix分级的癌症治疗 |
| JP2022540384A (ja) * | 2019-07-02 | 2022-09-15 | テリックス インターナショナル ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU6032786A (en) * | 1985-07-25 | 1987-01-29 | University Of Minnesota | Detection, imaging and therapy of renal cell carcinoma with monoclonal antibodies in vivo |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| WO1988008854A1 (en) * | 1987-05-06 | 1988-11-17 | Egbert Oosterwijk | Monoclonal antibodies to renal cell carcinoma |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE208403T1 (de) * | 1995-05-26 | 2001-11-15 | Merck Patent Gmbh | Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren |
| US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| EP2261229A3 (de) * | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glykosylierungs-Engineering von Antikörpern zur Verbesserung der antikörperabhängigen zellvermittelten Zytotoxizität |
| FR2793497B1 (fr) * | 1999-05-10 | 2003-04-18 | Centre Nat Rech Scient | Anticorps monoclonal dirige contre les cellules de carcinome renal humain |
| WO2001002431A1 (en) * | 1999-07-06 | 2001-01-11 | Got-A-Gene Ab | Recombinant adenovirus |
| GB0017720D0 (en) * | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| US20030040027A1 (en) * | 2001-08-16 | 2003-02-27 | Gerd Ritter | Method for determining protein component in a biological sample |
-
2002
- 2002-02-07 JP JP2002563309A patent/JP4263485B2/ja not_active Expired - Lifetime
- 2002-02-07 DE DE60214127T patent/DE60214127T2/de not_active Expired - Lifetime
- 2002-02-07 PT PT02704692T patent/PT1358318E/pt unknown
- 2002-02-07 WO PCT/EP2002/001282 patent/WO2002062972A2/en active IP Right Grant
- 2002-02-07 DK DK02704692T patent/DK1358318T3/da active
- 2002-02-07 WO PCT/EP2002/001283 patent/WO2002063010A2/en not_active Application Discontinuation
- 2002-02-07 CA CA2435683A patent/CA2435683C/en not_active Expired - Lifetime
- 2002-02-07 DK DK06014768.3T patent/DK1733736T3/en active
- 2002-02-07 EP EP02704692A patent/EP1358318B8/de not_active Expired - Lifetime
- 2002-02-07 MX MXPA03006992A patent/MXPA03006992A/es active IP Right Grant
- 2002-02-07 AT AT02704692T patent/ATE337395T1/de active
- 2002-02-07 PT PT60147683T patent/PT1733736E/pt unknown
- 2002-02-07 AU AU2002252999A patent/AU2002252999A1/en not_active Abandoned
- 2002-02-07 ES ES06014768.3T patent/ES2531909T3/es not_active Expired - Lifetime
- 2002-02-07 EP EP02722053A patent/EP1385959A2/de not_active Withdrawn
- 2002-02-07 AU AU2002238537A patent/AU2002238537B8/en not_active Expired
- 2002-02-07 ES ES02704692T patent/ES2266448T3/es not_active Expired - Lifetime
-
2003
- 2003-08-07 US US10/635,908 patent/US20040219633A1/en not_active Abandoned
-
2007
- 2007-03-02 HK HK07102381.6A patent/HK1094876A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4263485B2 (ja) | 2009-05-13 |
| US20040219633A1 (en) | 2004-11-04 |
| AU2002238537B2 (en) | 2006-07-20 |
| DK1733736T3 (en) | 2015-06-01 |
| DK1358318T3 (da) | 2007-01-02 |
| EP1358318B8 (de) | 2006-11-15 |
| DE60214127T2 (de) | 2007-01-11 |
| WO2002063010A3 (en) | 2003-11-27 |
| CA2435683A1 (en) | 2002-08-15 |
| JP2004522447A (ja) | 2004-07-29 |
| EP1358318B1 (de) | 2006-08-23 |
| HK1094876A1 (en) | 2007-04-13 |
| EP1358318A2 (de) | 2003-11-05 |
| ES2531909T3 (es) | 2015-03-20 |
| WO2002063010A9 (en) | 2002-09-12 |
| PT1733736E (pt) | 2015-06-11 |
| EP1385959A2 (de) | 2004-02-04 |
| ES2266448T3 (es) | 2007-03-01 |
| WO2002063010A2 (en) | 2002-08-15 |
| AU2002252999A1 (en) | 2002-08-19 |
| WO2002062972A2 (en) | 2002-08-15 |
| AU2002238537B8 (en) | 2006-08-24 |
| MXPA03006992A (es) | 2003-11-18 |
| WO2002062972A3 (en) | 2002-12-12 |
| CA2435683C (en) | 2012-03-20 |
| ATE337395T1 (de) | 2006-09-15 |
| PT1358318E (pt) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1094876A1 (en) | Method of producing recombinant antibodies against tumours | |
| EA200700249A1 (ru) | Рекомбинантное поликлональное антитело против резус-фактора d и способы его получения | |
| ATE481483T1 (de) | Verfahren zur herstellung eines rekombinanten polyklonalen proteins | |
| ATE501170T1 (de) | Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese | |
| ATE469917T2 (de) | Verfahren zur gewinnung von antikörpern | |
| NZ600584A (en) | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof | |
| DK1414858T3 (da) | Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf | |
| ATE405644T1 (de) | Verfahren zur herstellung und reinigung von erythropoietin | |
| ATE439380T1 (de) | Methoden zur herstellung humaner monoklonaler antikörper | |
| ATE449109T1 (de) | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung | |
| DE502006002453D1 (de) | Verfahren für die kontinuierliche zielgerichtete evolution von proteinen in vitro | |
| ATE500331T1 (de) | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden | |
| ATE424458T1 (de) | Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung | |
| ATE407987T1 (de) | Neue mesogene, verfahren zu deren herstellung und verwendung | |
| DE60310562D1 (de) | Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen | |
| MXPA03010523A (es) | Anticuerpos especificos para cd44v6. | |
| ATE360065T1 (de) | Verfahren zur herstellung von matrizen-dna und verfahren zur proteinherstellung in einem zellfreien proteinsynthesesystem unter verwendung davon | |
| DE60314132D1 (de) | Methode zur produktion monoklonaler antikörper | |
| DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
| DE502004007067D1 (de) | Verfahren zur herstellung zyklischer moleküle | |
| DE60228867D1 (de) | Verfahren zur herstellung und identifizierung löslicher proteindomänen | |
| ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
| ATE423467T1 (de) | Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften | |
| DE60329594D1 (de) | Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe | |
| ATE522543T1 (de) | Verfahren zur herstellung von reifem, rekombinantem milben-i-allergen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8381 | Inventor (new situation) |
Inventor name: OOSTERWIJK, EGBERT, NL-6641 BEUNINGEN, NL Inventor name: WARNAAR, SVEN, NL-2334 LEIDEN, NL Inventor name: ULLRICH, STEFAN, DR., 82319 STARNBERG, DE |
|
| 8364 | No opposition during term of opposition |